Navigation Links
UCI researchers discover key factor for survival of human embryonic stem cells

Human embryonic stem cells (hES) offer great hope for the treatment of some devastating diseases, but finding a way to keep enough of these cells usable and healthy for transplantation in patients has been an ongoing problem. Now scientists at UC Irvine have discovered a way to keep large quantities of these cells alive, a finding that could potentially lead to mass production of hES cells for therapeutic use at lower cost.

These findings appear in a paper in the early online version of the journal Nature Biotechnology.

UCI stem cell researchers Peter Donovan and Leslie Lock, along with April Pyle of Johns Hopkins University, found that molecules known as neurotrophins have a significant effect on whether hES cells survive in the laboratory. Although stem cells have the ability to self-renew and to differentiate into any cell in the body, it has been a challenge to keep them alive as single cells in an undifferentiated state.

In their studies, Donovan and Lock added neurotrophins to hES cells in the laboratory to see the effect they would have on cell survival. Neurotrophins normally encourage the survival of tissue in the nervous system. When three members of the family of neurotrophin growth factors ?brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4) ?were added to hES cells in culture, the cells' survival increased 36-fold.

"Keeping hES cells alive as single cells has been extremely difficult," Donovan said. "This fact has kept us from producing enough cells to be useful for therapy, and has limited our ability to genetically manipulate the cells, which we must do before they can be transplanted into patients. It appears that if we treat hES cells with neurotrophins, we can produce more of them faster and, hopefully, at much lower cost."

Understanding the role that neurotrophins play in stem cell survival could also help researchers with another major problem they face in usi
'"/>

Source:University of California - Irvine


Page: 1 2

Related biology news :

1. NYU researchers simulate molecular biological clock
2. Vital step in cellular migration described by UCSD medical researchers
3. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
4. UCSD researchers maintain stem cells without contaminated animal feeder layers
5. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
6. New protein discovered by Hebrew University researchers
7. First real-time view of developing neurons reveals surprises, say Stanford researchers
8. Agilent Technologies releases automated literature search tool for biology researchers
9. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
10. Yale researchers identify molecule for detecting parasitic infection in humans
11. US life expectancy about to decline, researchers say
Post Your Comments:
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... body's natural immune responses could be a target of future cancer ... of Medicine of the University of Southern California. , The ... of Pathology, is the first to identify how EphB4 ?a protein ... important aspect of this study is that ?if we turn the ...
... uncovered a new cellular secret that may explain how ... cancers that makes treatment especially difficult. If the mechanism ... can be understood well enough to manipulate it, new ... metastatic cancers. , Significance of the Mayo Clinic ...
... potentially powerful new therapy for treating diabetes, peripheral vascular ... and into animals by demonstrating it restores nerve and ... particularly important implications for the estimated 21 million Americans ... blood vessels. , The therapy involves netrins, a family ...
Cached Biology News:USC researchers investigate protein that protects tumors 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 3Proteins spur diabetic mice models to grow blood vessels, nerves 2
(Date:7/28/2015)... ZIONA, Israel , July ... (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing its ... today announced that Shomrat Shurtz has been appointed ... 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... 25 years of experience in marketing, regulatory and ...
(Date:7/27/2015)... and FRANKLIN, Tenn. ... a privately-owned  premier provider of health care services ... in the U.S., today announced that its parent ... signed a definitive agreement with Medical Properties Trust, ... acquisition of Capella for $900 million in cash.  The transaction ...
(Date:7/27/2015)... ... 2015 , ... Production of high tenacity filament yarn of viscose rayon (excluding ... For instance, it surpassed the EUR 106 million mark (in value terms) in 2013, ... a major producer, while Italy is a key consumer. , The high tenacity ...
(Date:7/27/2015)... Research presented at the 2015 AACC Annual Meeting & ... led to a fingerprick Ebola test becoming the first ... approval from the World Health Organization (WHO). This test ... West Africa by identifying suspected Ebola ... and treat these patients much faster than is currently ...
Breaking Biology Technology:CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
... , Revamilast is a PDE4 inhibitor, under development for ... successfully completed pre-clinical trials and Phase I studies , Phase ... UK , , Glenmark has initiated global  Phase IIb ... unmet medical need as globally they are over 300 million Asthma ...
... QinetiQ North America today announced the results of its ... experiment, which studied the effects of microgravity on host ... results of this experiment showed both the plants and ... (Biological Research In a Canister) homes on the shuttle. ...
... Bharat Renewable Energy Ltd (BREL) , a joint-venture of ... a program with SG Biofuels (SGB) to ... production of biodiesel in India. The program,s ... high performing hybrid varieties of Jatropha adapted to unique ...
Cached Biology Technology:Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 2Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 3Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 4QinetiQ North America Gains New Insights into Plant Growth and Sustainable Life Support on Final Shuttle Flight 2Bharat Renewable Energy Forms Alliance With SG Biofuels to Deploy Jatropha Hybrids for Biodiesel in India 2